Project Grant K99HL179380
Award Date
6/15/25
Completion Date
4/30/27
Dollars Obligated
$126K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This $500,089.80 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the role of inflammatory macrophages in cardiac remodeling and diastolic dysfunction associated with heart failure with preserved ejection fraction (HFPEF). The research aims to uncover the molecular, cellular, and functional mechanisms by which macrophages mediate fibroblast differentiation...
This $732,779 Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research focused on understanding the role of the serine-threonine kinase SGK1 in cardiometabolic heart failure with preserved ejection fraction (CMET HFPEF). The University of Arizona, as the prime awardee, will conduct studies to determine how cardiac-specific SGK1 regulates heart function, metabolism, and inter-organ...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $654,207 to The Johns Hopkins University to conduct research on the role of thrombospondin-1 (TSP-1) in heart failure with preserved ejection fraction (HFPEF). The goal is to identify the mechanisms by which TSP-1 activation modulates cardiac fibrosis and remodeling in HFPEF, particularly in relation to sex-specific...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support an investigation into the role of resistance exercise in the prevention and treatment of heart failure with preserved ejection fraction (HFpEF). The $117,789 award, with a period of performance from September 9, 2024 to August 31, 2026, will fund a research project led by Dr. McDonough at the University of Minnesota. The project...
This federal Project Grant award under the National Heart, Lung, and Blood Institute's (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) provides $2,185,454 in funding to Tufts Medical Center Parent, Inc. (Tufts Medical Center) to investigate the role of the FHOD3 gene variant in cardiomyopathy and heart failure. The research aims to understand how the FHOD3V1151I mutation impacts cardiac autophagy and remodeling, and whether personalized medicine strategies can modify this...
The University of Arizona was awarded a $625,316 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to investigate the role of RNA methylation and translational regulation in the oxidative stress response of heart failure. The research aims to elucidate how the YTHDF2 protein binds to methylated NRF2 mRNA to selectively induce its translation under oxidative stress, a process that may be impaired in end-stage heart failure. The...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $817,208 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Broad Institute, Inc. The grant will fund research to investigate the genetic basis and underlying mechanisms of heart failure using high-throughput cellular assays. The research aims to accelerate the functional interpretation of genes associated with heart failure risk identified through genome-wide association studies. The project...
This federal Project Grant award, valued at $564,445.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award, effective March 1, 2025 through December 31, 2031, supports the University of Texas Health Science Center at Houston's "Hypoxia-Inflammation Program" research focused on targeting hypoxia-inducible factors (HIFs) for the treatment of heart and lung diseases. The funded...
This Project Grant award for $616,914.00 was issued on January 1, 2025 by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The award supports research to elucidate the mechanisms by which the ubiquitin-proteasome system, specifically the UBE2O enzyme, regulates protein quality control and ribosome homeostasis during red blood cell differentiation. The research aims to reconstitute UBE2O-mediated proteasomal...